Loading
SSTR3 (Somatostatin receptor type 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase.
Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.50, genetic association 0.00, clinical 0.90).
In plain words · SSTR3 (Somatostatin receptor type 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
SSTR3 (Somatostatin receptor type 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase.
No product in this corpus aims at SSTR3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SSTR3: RNA tissue enhanced (brain 6 nTPM, lymphoid tissue 10 nTPM, testis 8 nTPM); blood lineage lineage enriched (T-cells 1 nTPM); high antibody staining in 4 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours); Open Targets associates it with 1 specific cancer type at or above 0.5 (carcinoid tumor). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SSTR3 tissue; Open Targets ENSG00000278195 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Yamada et al, Mol. Endocrinol, 1992, "Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase". Source.
Sources: HGNC HGNC:11332 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P32745 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000278195 (association with cancer (MONDO_0004992) 0.56; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.59 (GraphQL API, CC0))
Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. Location: Cell membrane (UniProt). Locus 22q13.1 (HGNC).
RNA: tissue enhanced (brain 6 nTPM, lymphoid tissue 10 nTPM, testis 8 nTPM), detected in some normal tissues. Blood: lineage enriched (T-cells 1 nTPM).
Medium: Cerebral cortex.
RNA cancer enhanced: Pancreatic Adenocarcinoma 3 pTPM.
No cancer stained high; medium in breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA SSTR3 tissue · HPA SSTR3 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SSTR3" OR ABSTRACT:"SSTR3" OR TITLE:"somatostatin receptor 3" OR ABSTRACT:"somatostatin receptor 3" OR TITLE:"Somatostatin receptor type 3" OR ABSTRACT:"Somatostatin receptor type 3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSTR3, not a curated reading list.